Irvine, CA-based Bright Uro has closed $23 million Series A financing led by Laborie Medical Technologies to achieve FDA 510(k) clearance of the Glean™ Urodynamics System, which enables wireless, catheter-free urodynamics to revolutionize the testing process by providing clinicians with more accurate data and actionable insights.

The Glean system is a very novel urology technology and this investment furthers our commitment to preserving and restoring human dignity while improving patient access and outcomes,” said Michael Frazzette, President & CEO of Laborie, a leading global provider of urology diagnostic and therapeutic solutions.

In just 15 months since securing an exclusive IP license from the Cleveland Clinic, we have developed, tested, and manufactured not a single device, but a highly complex system, including single-use disposable sensors, male and female insertion tools, a reusable uroflowmeter, and multiple software apps,” said Derek Herrera, Founder and CEO of Bright Uro.

en_GBEnglish (UK)